Dishman Carbogen Amcis Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/08y2ni7v5n8kko4146z50ig2.pdf

Key Takeaways


Revenue & Margin Drivers

Harshil Dalal: "We do expect that the revenue should grow exponentially from here on."

French Facility: From Drag to Driver

Harshil Dalal: "So, we have no doubts of ramping up the French facility quite significantly going forward."

Bavla: The FY27 Growth Engine

Harshil Dalal: "So progressively, what we will see in the next financial year is that QoQ, there should be an increase in the revenues coming out of the Bavla site. And in order to touch the INR 800 crores, the target is that we should be able to touch that over the next three years."

Strategic Partnerships & Pipeline

Stephan Fritschi: "I call this as a win-win-win situation because Carbogen Amcis benefits and profits of this collaboration because we can get more clients, different clients, which come from Celonic. The same is the case for Celonic itself. They get our clients in collaboration. And last but not least, but most important is that the client gets the benefit of this new one-stop shop feature we can offer out of us."

Integration & Digital Transformation


Balance Sheet & Capital Allocation

Harshil Dalal: "Our internal target is to get to the 25% ROCE margins over the next four years to five years. So, that is something which we are very much on track to achieve because we are looking at an extremely strong pipeline for Bavla."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth FY26Close to 8–10% total revenue growth for entire businessFY26
EBITDA margin FY26Expect to reach ~20% (from guided 18–20%) based on H1 results and H2 expectationsFY26
CDMO H2 mix shiftSecond half much stronger than first half; more commercial share of revenueH2 FY26
French facility EBITDA breakevenSurpass EUR 18 million EBITDA breakevenFY27
French facility full capacityReach full capacity utilizationClose to ~4 years
Bavla revenue targetReach INR 800 croresOver the next 3 years
CDMO revenue targetINR 3,000 crores (includes French facility, India, Bavla, Switzerland, Manchester, Shanghai)FY27
ROCE target25%Over next 4–5 years
CapEx FY26Close to INR 200–210 croresFY26
FundraiseINR 500–700 crores to retire Indian debtNo date given
SAP S/4HANA Swiss go-liveFourth phase go-liveNext 4–6 months

Key Metrics

MetricQ2 FY26
Revenue₹652.6 cr, vs ₹789 cr in Q2 FY25 (exceptionally high due to Q1 deferment)
EBITDA₹149 cr, H1 FY26 at ₹289.5 cr, up 64.4% YoY
EBITDA margin22.8%, vs 13.4% in H1 FY25; H1 FY26 at 21.3%
Profit after tax₹65 cr, vs ₹33 cr in Q2 FY25; H1 FY26 at ₹88.6 cr vs negative ₹44 cr in H1 FY25
CDMO revenue₹509 cr, degrowth vs Q2 FY25; H1 flat YoY; second half expected stronger
CDMO EBITDA margin25.3%, vs 19% in Q2 FY25; driven by late Phase 3 and ADC supplies to Japanese innovator
Marketable Molecules revenue₹143 cr, 85% growth vs Q2 FY25; H1 at ₹240 cr, 33.7% growth
Marketable Molecules EBITDA margin14%, vs 15.7% in Q2 FY25; Naroda/Quats margins lower; cholesterol and vitamin D analogues at ~18% margin
Revenue growth guidance FY268% to 10% total revenue growth expected
EBITDA margin guidance FY26~20%, up from earlier guided 18%–20%
CDMO revenue target FY27₹3,000 cr targeted
Net debtCHF 14.1 cr, vs CHF 15.7 cr as of March 31, 2025
CapEx$7.3 mn in Q2; $13 mn in H1; full year guidance ₹200–210 cr
Bavla site utilization20% to 25% currently; revenue target of ₹800 cr over next three years
French facility EBITDA breakeven€18 mn revenue; peak potential €45 mn at ~35% EBITDA margin
Development pipeline (Carbogen Amcis)CHF 15 cr as of September 30, 2025
Commercial order book (Carbogen Amcis)CHF 10 cr as of September 30, 2025
ROCE target25% over next 4–5 years